Processa Pharmaceuticals Stock Market Outlook
| PCSA Stock | USD 2.20 0.02 0.90% |
About 62% of all Processa Pharmaceuticals' investors are looking to take a long position. The analysis of the overall investor sentiment regarding Processa Pharmaceuticals suggests that some traders are interested. The current market sentiment, together with Processa Pharmaceuticals' historical and current headlines, can help investors time the market. In addition, many technical investors use Processa Pharmaceuticals stock news signals to limit their universe of possible portfolio assets.
Comfort Level 62
Interested
Panic | Confidence |
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Processa Pharmaceuticals' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Processa Pharmaceuticals.
News SentimentBullish | Hype SentimentBearish | Insider SentimentAcquiring |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Processa Pharmaceuticals is 'Strong Sell'. Macroaxis provides Processa Pharmaceuticals buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding PCSA positions.
Execute Processa Pharmaceuticals Advice
The Processa recommendation should be used to complement the investment advice compiled from the current analysts' consensus on Processa Pharmaceuticals. Macroaxis does not own or have any residual interests in Processa Pharmaceuticals or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Processa Pharmaceuticals' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Weakest | Details | |
Volatility | Dangerous | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Risky | Details | |
Economic Sensitivity | Moves indifferently to market moves | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Hold | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
For the selected time horizon Processa Pharmaceuticals has a Mean Deviation of 8.18, Standard Deviation of 18.23 and Variance of 332.38We provide trade recommendations to complement the recent expert consensus on Processa Pharmaceuticals. Our dynamic recommendation engine exercises a multidimensional algorithm to analyze the firm's potential to grow using all technical and fundamental data available at the time. To make sure Processa Pharmaceuticals is not overpriced, please check all Processa Pharmaceuticals fundamentals, including its cash flow from operations, beta, and the relationship between the debt to equity and price to earnings to growth . Please also confirm Processa Pharmaceuticals price to book to check out your buy or sell decision is consistent with all fundamental data available and that the company can sustain itself in the current economic cycle.
Processa Pharmaceuticals Trading Alerts and Improvement Suggestions
| Processa Pharmaceuticals generated a negative expected return over the last 90 days | |
| Processa Pharmaceuticals has high historical volatility and very poor performance | |
| Processa Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (11.85 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Processa Pharmaceuticals currently holds about 12.06 M in cash with (11.25 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.76. | |
| Processa Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: Alliance Entertainment and Processa Pharmaceuticals Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TV - Erie Times-News |
Processa Pharmaceuticals Returns Distribution Density
The distribution of Processa Pharmaceuticals' historical returns is an attempt to chart the uncertainty of Processa Pharmaceuticals' future price movements. The chart of the probability distribution of Processa Pharmaceuticals daily returns describes the distribution of returns around its average expected value. We use Processa Pharmaceuticals price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Processa Pharmaceuticals returns is essential to provide solid investment analysis for Processa Pharmaceuticals.
| Mean Return | -0.77 | Value At Risk | -14.08 | Potential Upside | 10.24 | Standard Deviation | 18.23 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Processa Pharmaceuticals historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Processa Stock Institutional Investors
| Shares | Sbi Securities Co Ltd | 2025-06-30 | 12.0 | Advisor Group Holdings, Inc. | 2025-06-30 | 2.0 | Miracle Mile Advisors, Inc. | 2025-06-30 | 0.0 | Armistice Capital, Llc | 2025-06-30 | 0.0 | Hrt Financial Llc | 2025-03-31 | 0.0 | Virtu Financial Llc | 2025-06-30 | 104.7 K | Ubs Group Ag | 2025-06-30 | 64.6 K | Alpine Partners Vi, Llc | 2025-06-30 | 53.4 K | Geode Capital Management, Llc | 2025-06-30 | 50.6 K | Cubist Systematic Strategies, Llc | 2025-06-30 | 41.8 K | Vanguard Group Inc | 2025-06-30 | 24.4 K |
Processa Pharmaceuticals Cash Flow Accounts
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Free Cash Flow | (8.7M) | (9.6M) | (8.1M) | (11.2M) | (10.1M) | (9.6M) | |
| Net Income | (11.4M) | (27.4M) | (11.1M) | (11.9M) | (10.7M) | (11.2M) | |
| Change In Cash | 1.1M | (10.0M) | (1.8M) | (3.5M) | (3.2M) | (3.0M) | |
| Other Non Cash Items | 220.6K | 7.7M | 1.4M | 87.2K | 100.3K | 95.2K | |
| End Period Cash Flow | 16.5M | 6.5M | 4.7M | 1.2M | 1.4M | 1.3M | |
| Depreciation | 791.0K | 788.5K | 222.0 | 782.0 | 899.3 | 854.33 |
Processa Pharmaceuticals Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Processa Pharmaceuticals or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Processa Pharmaceuticals' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Processa stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.77 | |
β | Beta against Dow Jones | -0.18 | |
σ | Overall volatility | 18.65 | |
Ir | Information ratio | -0.05 |
Processa Pharmaceuticals Volatility Alert
Processa Pharmaceuticals is displaying above-average volatility over the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Processa Pharmaceuticals' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Processa Pharmaceuticals' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Processa Pharmaceuticals Fundamentals Vs Peers
Comparing Processa Pharmaceuticals' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Processa Pharmaceuticals' direct or indirect competition across all of the common fundamentals between Processa Pharmaceuticals and the related equities. This way, we can detect undervalued stocks with similar characteristics as Processa Pharmaceuticals or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Processa Pharmaceuticals' fundamental indicators could also be used in its relative valuation, which is a method of valuing Processa Pharmaceuticals by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Processa Pharmaceuticals to competition |
| Fundamentals | Processa Pharmaceuticals | Peer Average |
| Return On Equity | -2.71 | -0.31 |
| Return On Asset | -1.3 | -0.14 |
| Current Valuation | (1.28 M) | 16.62 B |
| Shares Outstanding | 2.27 M | 571.82 M |
| Shares Owned By Insiders | 10.76 % | 10.09 % |
| Shares Owned By Institutions | 9.83 % | 39.21 % |
| Number Of Shares Shorted | 29.97 K | 4.71 M |
| Price To Book | 0.86 X | 9.51 X |
| EBITDA | (12.05 M) | 3.9 B |
| Net Income | (11.85 M) | 570.98 M |
| Cash And Equivalents | 12.06 M | 2.7 B |
| Cash Per Share | 0.76 X | 5.01 X |
| Total Debt | 73.51 K | 5.32 B |
| Debt To Equity | 0 % | 48.70 % |
| Current Ratio | 8.89 X | 2.16 X |
| Book Value Per Share | 2.76 X | 1.93 K |
| Cash Flow From Operations | (11.25 M) | 971.22 M |
| Short Ratio | 0.32 X | 4.00 X |
| Earnings Per Share | (28.75) X | 3.12 X |
| Price To Earnings To Growth | (0.12) X | 4.89 X |
| Target Price | 25.0 | |
| Number Of Employees | 10 | 18.84 K |
| Beta | 1.02 | -0.15 |
| Market Capitalization | 5.03 M | 19.03 B |
| Total Asset | 3.23 M | 29.47 B |
| Retained Earnings | (87.22 M) | 9.33 B |
| Working Capital | 340.99 K | 1.48 B |
| Net Asset | 3.23 M |
Note: Acquisition by Patrick Lin of 3 shares of Processa Pharmaceuticals subject to Rule 16b-3 [view details]
Processa Pharmaceuticals Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Processa . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
Processa Pharmaceuticals Target Price Consensus
Processa target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Processa Pharmaceuticals' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| One | Hold |
Most Processa analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Processa stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Processa Pharmaceuticals, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationProcessa Pharmaceuticals Target Price Projection
Processa Pharmaceuticals' current and average target prices are 2.20 and 25.00, respectively. The current price of Processa Pharmaceuticals is the price at which Processa Pharmaceuticals is currently trading. On the other hand, Processa Pharmaceuticals' target price is what analysts think the stock is worth. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Processa Pharmaceuticals Market Quote on 16th of February 2026
Target Price
Analyst Consensus On Processa Pharmaceuticals Target Price
Processa Pharmaceuticals Analyst Ratings
Processa Pharmaceuticals' analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Processa Pharmaceuticals stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Processa Pharmaceuticals' financials, market performance, and future outlook by experienced professionals. Processa Pharmaceuticals' historical ratings below, therefore, can serve as a valuable tool for investors.Analyst Consensus Breakdown
Average Consensus Estimates
About Processa Pharmaceuticals Buy or Sell Advice
When is the right time to buy or sell Processa Pharmaceuticals? Buying financial instruments such as Processa Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Processa Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Compulsion Thematic Idea Now
Compulsion
Companies involved in research, development, and manufacturing of products with compulsion characteristics such as cigarettes, addictive drugs and alcohol. The Compulsion theme has 40 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Compulsion Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Processa Pharmaceuticals Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For information on how to trade Processa Stock refer to our How to Trade Processa Stock guide.You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Processa Pharmaceuticals. Anticipated expansion of Processa directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Processa Pharmaceuticals assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Investors evaluate Processa Pharmaceuticals using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Processa Pharmaceuticals' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause Processa Pharmaceuticals' market price to deviate significantly from intrinsic value.
It's important to distinguish between Processa Pharmaceuticals' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Processa Pharmaceuticals should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Processa Pharmaceuticals' market price signifies the transaction level at which participants voluntarily complete trades.